Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Sandoz Lays Out Plan For Rebound With Top Line Stagnant In 2021
Core Operating Profit Falls By 12% As Reported; 14% In Constant Currencies
Feb 04 2022
•
By
Dean Rudge
Novartis continues to plot a rebound for Sandoz • Source: Alamy
More from Earnings
More from Business
